
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2090546/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Aging and vascular endothelial function in humans. Clinical Science, 2011, 120, 357-375.	4.3	531
2	A guiding map for inflammation. Nature Immunology, 2017, 18, 826-831.	14.5	506
3	25-Hydroxyvitamin D Deficiency Is Associated With Inflammation-Linked Vascular Endothelial Dysfunction in Middle-Aged and Older Adults. Hypertension, 2011, 57, 63-69.	2.7	301
4	Vascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthase. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H425-H432.	3.2	250
5	Aging is associated with greater nuclear NFκB, reduced IκBα, and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humans. Aging Cell, 2008, 7, 805-812.	6.7	213
6	Dietary Sodium Restriction Reverses Vascular Endothelial Dysfunction in Middle-Aged/Older Adults With Moderately Elevated Systolic Blood Pressure. Journal of the American College of Cardiology, 2013, 61, 335-343.	2.8	126
7	Strategies for Achieving Healthy Vascular Aging. Hypertension, 2018, 71, 389-402.	2.7	106
8	Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2018, 29, 571-578.	6.1	101
9	Vascular calcification in endâ€stage renal disease. Hemodialysis International, 2013, 17, S17-21.	0.9	78
10	High-dose ascorbic acid infusion abolishes chronic vasoconstriction and restores resting leg blood flow in healthy older men. Journal of Applied Physiology, 2007, 103, 1715-1721.	2.5	76
11	IL-1 Inhibition and Vascular Function in CKD. Journal of the American Society of Nephrology: JASN, 2017, 28, 971-980.	6.1	66
12	Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 577-584.	4.5	65
13	Dietary Sodium Restriction and Association with Urinary Marinobufagenin, Blood Pressure, and Aortic Stiffness. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1952-1959.	4.5	63
14	Low 25-hydroxyvitamin D level is independently associated with non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 792-798.	2.6	59
15	Vascular Function and Uric Acid-Lowering in Stage 3 CKD. Journal of the American Society of Nephrology: JASN, 2017, 28, 943-952.	6.1	56
16	Does inflammation affect outcomes in dialysis patients?. Seminars in Dialysis, 2018, 31, 388-397.	1.3	55
17	Effect of Treatment of Metabolic Acidosis on Vascular Endothelial Function in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1463-1470.	4.5	47
18	Vitamin D Level and Risk of Community-Acquired Pneumonia and Sepsis. Nutrients, 2014, 6, 2196-2205.	4.1	45

2

#	Article	IF	CITATIONS
19	Low dietary sodium intake is associated with enhanced vascular endothelial function in middle-aged and older adults with elevated systolic blood pressure. Therapeutic Advances in Cardiovascular Disease, 2009, 3, 347-356.	2.1	44
20	Regular aerobic exercise protects against impaired fasting plasma glucose-associated vascular endothelial dysfunction with aging. Clinical Science, 2013, 124, 325-331.	4.3	42
21	Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1493-1501.	4.5	40
22	Apoptosis and autophagy in polycystic kidney disease (PKD). Cellular Signalling, 2020, 68, 109518.	3.6	39
23	Cholecalciferol, Calcitriol, and Vascular Function in CKD: A Randomized, Double-Blind Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1438-1446.	4.5	38
24	Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2017, 32, 342-347.	0.7	36
25	Serum Sodium and Cognition in Older Community-Dwelling Men. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 366-374.	4.5	30
26	Overweight and Obesity and Progression of ADPKD. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 908-915.	4.5	30
27	Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease. American Journal of Nephrology, 2016, 44, 171-178.	3.1	28
28	Fibroblast Growth Factor 23 and the Risk of Infection-Related Hospitalization in Older Adults. Journal of the American Society of Nephrology: JASN, 2017, 28, 1239-1246.	6.1	26
29	Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study. American Journal of Kidney Diseases, 2022, 79, 518-526.	1.9	26
30	Cytochrome P-450 2C9 signaling does not contribute to age-associated vascular endothelial dysfunction in humans. Journal of Applied Physiology, 2008, 105, 1359-1363.	2.5	23
31	Tetrahydrobiopterin Supplementation Enhances Carotid Artery Compliance in Healthy Older Men: A Pilot Study. American Journal of Hypertension, 2012, 25, 1050-1054.	2.0	22
32	IL-1 Inhibition and Function of the HDL-Containing Fraction of Plasma in Patients with Stages 3 to 5 CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 702-711.	4.5	22
33	Dietary Sodium/Potassium Intake Does Not Affect Cognitive Function or Brain Imaging Indices. American Journal of Nephrology, 2018, 47, 57-65.	3.1	21
34	Effect of Dietary Sodium Restriction on Human Urinary Metabolomic Profiles. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1227-1234.	4.5	18
35	Vascular endothelial function is not related to serum uric acid in healthy adults. American Journal of Hypertension, 2012, 25, 407-413.	2.0	17
36	Assessment of Vascular Function in Patients With Chronic Kidney Disease. Journal of Visualized Experiments, 2014, , .	0.3	16

#	Article	IF	CITATIONS
37	Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease. IScience, 2022, 25, 103697.	4.1	16
38	25-vitamin D, 1,25-vitamin D, parathyroid hormone, fibroblast growth factor-23 and cognitive function in men with advanced CKD: a veteran population. Clinical Nephrology, 2014, 82 (2014), 296-303.	0.7	15
39	Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post-hoc analysis of a randomized clinical trial. PLoS ONE, 2018, 13, e0205831.	2.5	13
40	Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2019, 74, 213-223.	1.9	13
41	Curcumin therapy to treat vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease: Design and baseline characteristics of participants. Contemporary Clinical Trials Communications, 2020, 19, 100635.	1.1	13
42	Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies. Kidney Medicine, 2021, 3, 536-545.e1.	2.0	11
43	Interleukin-1 inhibition, chronic kidney disease-mineral and bone disorder, and physical function. Clinical Nephrology, 2017, 88, 132-143.	0.7	11
44	Mineral Metabolites, Angiotensin II Inhibition and Outcomes in Advanced Chronic Kidney Disease. American Journal of Nephrology, 2015, 42, 361-368.	3.1	8
45	Vascular Dysfunction, Oxidative Stress, and Inflammation in Chronic Kidney Disease. Kidney360, 2020, 1, 501-509.	2.1	8
46	Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults with ADPKD. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 240-250.	4.5	8
47	Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients. Kidney International Reports, 2019, 4, 1742-1748.	0.8	5
48	Serum Sodium and Pulse Pressure in SPRINT. American Journal of Hypertension, 2019, 32, 649-656.	2.0	5
49	Association of Monocyte Count and Monocyte/Lymphocyte Ratio with the Risk of Cardiovascular Outcomes in Patients with CKD. Kidney360, 2022, 3, 657-665.	2.1	5
50	Renal outcomes and dietary potassium: the overshadowed electrolyte?. Kidney International, 2014, 86, 1077-1078.	5.2	4
51	Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease. Kidney360, 2020, 1, 648-656.	2.1	4
52	Affected parent sex and severity of autosomal dominant polycystic kidney disease: a retrospective cohort study. Clinical Nephrology, 2018, 89, 196-204.	0.7	4
53	Cystatin-C-based eGFR: what is it telling us?. Nature Reviews Nephrology, 2013, 9, 318-319.	9.6	3
54	Dietary Sodium Restriction Decreases Urinary Ngal in Older Adults with Moderately Elevated Systolic Blood Pressure Free from Chronic Kidney Disease. Journal of Investigative Medicine, 2020, 68, 1271-1275.	1.6	2

#	Article	IF	CITATIONS
55	Should statin therapy be expanded in patients with CKD?. Nature Reviews Nephrology, 2012, 8, 440-441.	9.6	1
56	Management of Mineral and Bone Disorders in Chronic Kidney Disease. , 2020, , 1013-1033.		1
57	PKD1 Compared With PKD2 Genotype and Cardiac Hospitalizations in the Halt Progression of Polycystic Kidney Disease Studies. Kidney International Reports, 2022, 7, 117-120.	0.8	1
58	A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD. Kidney360, 2021, 2, 224-235.	2.1	1
59	Frequent Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 707-710.	4.5	Ο
60	Posthemodialysis Weights and Mortality. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 729-731.	4.5	0
61	Arterial Stiffness Is Independently Associated with Acute Kidney Injury in SPRINT. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, CJN.06420521.	4.5	О